305 related articles for article (PubMed ID: 30834050)
21. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
[TBL] [Abstract][Full Text] [Related]
22. [Effect of dNLR and LIPI scores on the prognosis of elderly patients with non-surgical treatment of non-small cell lung cancer].
Xie JH; Liu MM; Sun NN; Zhang L; Zhang HZ
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):975-980. PubMed ID: 36164700
[No Abstract] [Full Text] [Related]
23. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.
Zhou Q; Deng G; Wang Z; Dai G
Front Surg; 2022; 9():1002075. PubMed ID: 36684178
[TBL] [Abstract][Full Text] [Related]
24. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
[TBL] [Abstract][Full Text] [Related]
25. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
[TBL] [Abstract][Full Text] [Related]
26. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
Chan SWS; Smith E; Aggarwal R; Balaratnam K; Chen R; Hueniken K; Fazelzad R; Weiss J; Jiang S; Shepherd FA; Bradbury PA; Sacher AG; Leighl NB; Xu W; Brown MC; Eng L; Liu G
Clin Lung Cancer; 2021 Sep; 22(5):390-407. PubMed ID: 33582072
[TBL] [Abstract][Full Text] [Related]
27. The Lung Immune Prognostic Index May Predict the Efficacy of Different Treatments in Patients with Advanced NSCLC: A Meta-Analysis.
Xie J; Zang Y; Liu M; Peng L; Zhang H
Oncol Res Treat; 2021; 44(4):164-175. PubMed ID: 33657566
[TBL] [Abstract][Full Text] [Related]
28. Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy.
Araki T; Tateishi K; Komatsu M; Sonehara K; Kanda S; Hanaoka M; Koizumi T
Thorac Cancer; 2022 Apr; 13(7):1006-1013. PubMed ID: 35156310
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
[TBL] [Abstract][Full Text] [Related]
30. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
[TBL] [Abstract][Full Text] [Related]
32. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.
Xiong A; Xu J; Wang S; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Nie W; Zhong H; Zhang X
Front Immunol; 2023; 14():1173025. PubMed ID: 37304273
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Parent P; Auclin E; Patrikidou A; Mezquita L; Martínez Chanzá N; Dumont C; Rodriguez-Vida A; Llacer C; Lozano R; Ratta R; Merseburger AS; Sternberg CN; Baciarello G; Colomba E; Fuerea A; Besse B; Loriot Y; Lavaud P
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831409
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
[TBL] [Abstract][Full Text] [Related]
35. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis.
Huang L; Han H; Zhou L; Chen X; Xu Q; Xie J; Zhan P; Chen S; Lv T; Song Y
Front Oncol; 2021; 11():670230. PubMed ID: 34249708
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Qi W; Zhao S; Chen J
Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
[TBL] [Abstract][Full Text] [Related]
38. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
Meyers DE; Stukalin I; Vallerand IA; Lewinson RT; Suo A; Dean M; North S; Pabani A; Cheng T; Heng DYC; Bebb DG; Morris DG
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684111
[TBL] [Abstract][Full Text] [Related]
39. Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity.
Moratiel Pellitero A; Zapata Garcia M; Gascon Ruiz M; Arbones-Mainar JM; Lastra Del Prado R; Isla D
World J Oncol; 2024 Apr; 15(2):223-238. PubMed ID: 38545481
[TBL] [Abstract][Full Text] [Related]
40. Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy.
Ali WAS; Hui P; Ma Y; Wu Y; Zhang Y; Chen Y; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L
Ann Transl Med; 2021 Nov; 9(22):1639. PubMed ID: 34988148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
